NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Publication
, Journal Article
Thompson, JA; Schneider, BJ; Brahmer, J; Andrews, S; Armand, P; Bhatia, S; Budde, LE; Costa, L; Davies, M; Dunnington, D; Ernstoff, MS ...
Published in: J Natl Compr Canc Netw
March 2020
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2020
Volume
18
Issue
3
Start / End Page
230 / 241
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasms
- Immunotherapy
- Humans
- Antineoplastic Agents, Immunological
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Engh, A. (2020). NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw, 18(3), 230–241. https://doi.org/10.6004/jnccn.2020.0012
Thompson, John A., Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, et al. “NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.” J Natl Compr Canc Netw 18, no. 3 (March 2020): 230–41. https://doi.org/10.6004/jnccn.2020.0012.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230–41.
Thompson, John A., et al. “NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.” J Natl Compr Canc Netw, vol. 18, no. 3, Mar. 2020, pp. 230–41. Pubmed, doi:10.6004/jnccn.2020.0012.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar;18(3):230–241.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2020
Volume
18
Issue
3
Start / End Page
230 / 241
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasms
- Immunotherapy
- Humans
- Antineoplastic Agents, Immunological
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis